Neonatal persistent pulmonary hypertension treated with milrinone: Four case reports

Biology of the Neonate

Volumn 89, Issue 1, 2006, Pages 1-5

  Bassler, Dirk ^a   Choong, Karen ^a   McNamara, Patrick ^b   Kirpalani, Haresh ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Inhaled nitric oxide; Milrinone; Neonatal persistent pulmonary hypertension

Indexed keywords

MILRINONE; PHOSPHODIESTERASE III INHIBITOR;

ARTICLE; CASE REPORT; EXTUBATION; FEMALE; HUMAN; INTENSIVE CARE; LUNG HEMODYNAMICS; LUNG INFLATION; NEWBORN; OXYGENATION; PEDIATRIC CARDIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZATION; SURVIVAL RATE; VASODILATATION;

ADMINISTRATION, INHALATION; ANIMALS; ANOXEMIA; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MECONIUM ASPIRATION SYNDROME; MILRINONE; NITRIC OXIDE; OLIGOHYDRAMNIOS; PERSISTENT FETAL CIRCULATION SYNDROME; PHOSPHODIESTERASE INHIBITORS; PREGNANCY;

EID: 30644470815     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088192     Document Type: Article

References (10)

1. Travadi JN, Patole SK: Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol 2003;36:529-535.
2. Finer NN, Barrington KJ: Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2001;4:CD 000399.
3. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure: The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336:597-604.
4. Matot I, Gozal Y: Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 2004;125:644-651.
5. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al: Efficacy and safety of Milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107:996-1002.
6. Theilitz S, Oishi P, Sanchez LS, Bekker JM, Ovadia B, Johengen MJ, et al: Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. Pediatr Crit Care Med 2004;5:234-239.
7. Deb B, Bradford K, Pearl RG: Additive effects of inhaled nitric oxide and intravenous Milrinone in experimental pulmonary hypertension. Crit Care Med 2000;28:795-799.
8. Paradisis M, Evans N, Osborn D, Kluckow M, McLachlan A: Pilot study of Milrinone for prevention of low systemic blood flow in very preterm infants. ESPR, 2004.
9. Laique FR, Whyte HE, McNamara PJ: Inodilator therapy in severe Persistent Pulmonary Hypertension of the Newborn (PPHN): Does intravenous Milrinone improve oxygenation? Pediatr Res 2004;42:525A.
10. Tanaka H, Tajimi K, Moritsune O, Kobayashi K, Okada K: Effects of Milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit Care Med 1991;19:68-74.